Pharmacodynamic Effects of Dabigatran in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel

Trial Profile

Pharmacodynamic Effects of Dabigatran in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Aspirin; Clopidogrel
  • Indications Coronary artery disease; Myocardial infarction; Stroke; Thrombosis; Venous thromboembolism
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Dec 2015 Primary endpoint has not been met. (TRAP-induced Platelet Aggregation), as published in the Thrombosis and Haemostasis
    • 03 Dec 2015 Results published in the Thrombosis and Haemostasis
    • 25 Mar 2015 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top